B+
Bull case
25%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-09-20 · RankAlpha Sentiment Codex
MDAI
Spectral AICNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
FDA clearance removes a major regulatory barrier, while the planned U.S. launch, potential UKCA expansion, and BARDA-supported development provide several paths toward commercialization.
Posture
Mixed
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-11-10 · AMC.
What can break
Current revenue and margins remain influenced by government-funded development work; commercial pricing, recurring service revenue, and product-level margins have not yet been demonstrated at scale.
Momentum
72
Value
36
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.80 · Bull $3.50 · Bear $0.70Analysis 2026-09-20; returns require an exact persisted reference.
Earnings
2026-11-10 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-11-06 • Vendor: Data Vendor v1
Scores
As of 2026-11-06 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-11-06
Investment thesis
As of 2026-11-06
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-11-06. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $5.11
Why
Momentum72 · Δ7d -
Value36 · Δ7d -0.0
Sentiment67 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-11-10 · AMC.
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Current revenue and margins remain influenced by government-funded development work; commercial pricing, recurring service revenue, and product-level margins have not yet been demonstrated at scale.
- • Hospital procurement, cybersecurity review, installation, and clinician-adoption cycles could delay first commercial sales beyond management's year-end 2026 objective.
- • Commercial demand, procurement speed, recurring economics, and sustainable margins remain unproven.
Catalyst clock
2026-11-10 · AMC
UKCA label-expansion decision
Lead driver: Sentiment · See AI snapshot
Momentum
72
18% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
36
43% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
67
39% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 72.1 / Value 36.4 / Sentiment 66.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-20. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-09-20 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-09-20 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-11-06
Fundamentals (TTM)
As of 2026-11-06
Market Cap
$47.96M
Beta
0.94
Shares Out
32.18M
P/E (TTM) · Derived
-5.2
P/S (TTM)
2.11
P/FCF (TTM) · Derived
-3.51
Rev YoY
-30.4%
EPS YoY
-58.5%
Gross Margin
+41.5%
Op Margin
-79.9%
Net Debt
-$5.3M
Current Ratio
0.90
As of 2026-11-06 • Updated nightlySource: Internal modelMethods & Data